Histopathological findings associated with complete clinical remission in patients with lupus nephritis
Main Article Content
Keywords
Lupus Nephritis, Biopsy, Pathology, Renal Remission, Cohort Studies
Abstract
Abstract
Background: Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus. Patients who do not achieve remission have a 10-year renal survival rate of 19%.
Objective: To evaluate the histopathological findings of LN associated with complete remission > 12 months after kidney biopsy.
Material and methods: Retrospective cohort of adults with lupus (2019 EULAR/ACR criteria) who underwent kidney biopsy between January 2017 and December 2021. Clinical, biochemical, and histopathological data were collected at the time of biopsy; renal function (serum creatinine, estimated glomerular filtration rate [eGFR], and proteinuria/day) was measured throughout the study (end of follow-up in June 2023).
Results: Thirty-eight patients were included. When comparing the non-remission group (n = 13) with the complete remission group (n = 18), only the degree of interstitial fibrosis and tubular atrophy (IFTA) (grade 2: 46% vs. 11%, respectively) and the chronicity index [5.0 (4.0–6.5) vs. 3.0 (1.0–5.0)] showed significant differences (p < 0.05). At the end of the study, the non-remission group, compared with the complete remission group, had lower eGFR [57 (10–100) vs. 104 (87–123) mL/min/1.73 m², p < 0.05] and higher proteinuria [4.00 (1.82–8.00) vs. 0.25 (0.16–0.39) g/day, p < 0.05]. In the logistic regression analysis, only proteinuria [OR 0.72 (95%CI 0.54–0.98), p = 0.03] predicted remission.
Conclusions: The histopathological findings associated with complete LN remission > 12 months were lower IFTA and a lower chronicity index. In the multivariate analysis, the only significant variable predicting remission was baseline proteinuria.
References
1. Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clinical Journal of the American Society of Nephrology. 2017;12(5):825–35.
2. Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, et al. 2019 Update of the Joint European League against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020 Jun 1;79(6):S713–23.
3. KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS. Kidney Int. 2024 Jan 1;105(1):S1–69.
4. Kang Y, Zuo Y, He M, Duo L, Chen X, Tang W. Clinical predictive model to estimate probability of remission in patients with lupus nephritis. Int Immunopharmacol. 2022 Sep 1;110.
5. Palazzo L, Lindblom J, Mohan C, Parodis I. Current Insights on Biomarkers in Lupus Nephritis: A Systematic Review of the Literature. Vol. 11, Journal of Clinical Medicine. MDPI; 2022.
6. Roveta A, Parodi EL, Brezzi B, Tunesi F, Zanetti V, Merlotti G, et al. Lupus Nephritis from Pathogenesis to New Therapies: An Update. Vol. 25, International Journal of Molecular Sciences. Multidisciplinary Digital Publishing Institute (MDPI); 2024.
7. Parodis I, Tamirou F, Houssiau FA. Prediction of prognosis and renal outcome in lupus nephritis. Vol. 7, Lupus Science and Medicine. BMJ Publishing Group; 2020.
8. Mejía-Vilet JM, Córdova-Sánchez BM, Uribe-Uribe NO, Correa-Rotter R, Morales-Buenrostro LE. Prognostic significance of renal vascular pathology in lupus nephritis. Lupus. 2017 Sep 1;26(10):1042–50.
9. Zavala-Miranda MF, Perez-Arias AA, Marquez-Macedo SE, Comunidad-Bonilla RA, Romero-Diaz J, Morales-Buenrostro LE, et al. Characteristics and outcomes of a Hispanic lupus nephritis cohort from Mexico. Rheumatology (United Kingdom). 2023 Mar 1;62(3):1136–44.
10. Ameh OI, Ekrikpo U, Bello A, Okpechi I. Current management strategies of chronic kidney disease in resource-limited countries. Vol. 13, International Journal of Nephrology and Renovascular Disease. Dove Medical Press Ltd; 2020. p. 239–51.
11. Fletcher BR, Damery S, Aiyegbusi OL, Anderson N, Calvert M, Cockwell P, et al. Symptom burden and health-related quality of life in chronic kidney disease: A global systematic review and meta-analysis. Vol. 19, PLoS Medicine. Public Library of Science; 2022.
12. Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race. New England Journal of Medicine. 2021 Nov 4;385(19):1737–49.
13. Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, Cook HT, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018 Apr 1;93(4):789–96.
14. Barber MRW, Drenkard C, Falasinnu T, Hoi A, Mak A, Kow NY, et al. Global epidemiology of systemic lupus erythematosus. Vol. 17, Nature Reviews Rheumatology. Nature Research; 2021. p. 515–32.
15. Xiang W, Xia X, Lu Y, Zhang X, Shi X, Jia X, et al. Sex differences in mortality among patients with lupus nephritis. Eur J Med Res. 2024 Oct 18;29(1):500.
16. Arnaud L, Tektonidou MG. Long-term outcomes in systemic lupus erythematosus: Trends over time and major contributors. Rheumatology (United Kingdom). 2020 Dec 1;59:V29–38.
17. Petri M, Barr E, Magder LS. Risk of renal failure within 10 or 20 years of systemic lupus erythematosus diagnosis. Journal of Rheumatology. 2021 Feb 1;48(2):222–7.
18. Hall JE, Mouton AJ, Da Silva AA, Wang Z, Li X, Do Carmo JM. Obesity, kidney dysfunction, and inflammation: interactions in hypertension. Vol. 117, Cardiovascular Research. Oxford University Press; 2021. p. 1859–76.
19. Ikeuchi H, Sugiyama H, Sato H, Yokoyama H, Maruyama S, Mukoyama M, et al. A nationwide analysis of renal and patient outcomes for adults with lupus nephritis in Japan. Clin Exp Nephrol. 2022 Sep 1;26(9):898–908.
20. Luís MSF, Bultink IEM, Da Silva JAP, Voskuyl AE, Ines LS. Early predictors of renal outcome in patients with proliferative lupus nephritis: A 36-month cohort study. Rheumatology (United Kingdom). 2021 Nov 1;60(11):5134–41.
21. Zoshima T, Hara S, Suzuki K, Yoshida M, Konishi M, Hibino S, et al. Long-term outcomes of lupus nephritis with low-level proteinuria: a multicentre, retrospective study. Rheumatology. 2023 Nov 1;
22. Leatherwood C, Speyer CB, Feldman CH, D’Silva K, Gómez-Puerta JA, Hoover PJ, et al. Clinical characteristics and renal prognosis associated with interstitial fibrosis and tubular atrophy (IFTA) and vascular injury in lupus nephritis biopsies. Semin Arthritis Rheum. 2019 Dec 1;49(3):396–404.
23. Yu F, Wu LH, Tan Y, Li LH, Wang CL, Wang WK, et al. Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system. Kidney Int. 2010 May;77(9):820–9.
24. Moroni G, Porata G, Raffiotta F, Quaglini S, Frontini G, Sacchi L, et al. Beyond ISN/RPS Lupus Nephritis Classification: Adding Chronicity Index to Clinical Variables Predicts Kidney Survival. Kidney360. 2022 Jan 27;3(1):122–32.
25. Ramya Lakshmi V, Vangala N, Uppin MS, Gudithi S, Taduri G, Raju SB. Revisiting vasculopathy in lupus nephritis: A renal biopsy evaluation study. Indian J Nephrol. 2022 Jan 1;32(1):28–33.
26. Lin KY kit, Chan EY hin, Mak YF, To MC, Wong SW, Lai FF yee, et al. Renal vascular lesions in childhood-onset lupus nephritis. Pediatric Nephrology. 2024 Jan 1;
Article Sidebar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.